Conclusions
Although the outcome of severe forms of glomerulonephritis has improved over recent years, there has to be a realistic sense of disappointment related to the lack of immunologically specific treatment available, reflected in the overall similarity of the management of these patients. The sense of disappointment is heightened by the lack of properly conducted trials containing an adequate number of subjects to answer the relatively simple questions posed in everyday nephrological practice. With the advent of the more specific immunological therapies outlined above and the development in some diseases of particular immunopathogenetic markers, there are reasons for an optimistic view of the future; this must be tempered by the hope that new forms of therapy will be properly assessed.
Similar content being viewed by others
References
Adelman NE, Watling DL, McDevitt HO (1983) Treatment of (NZB × NZW) F1 disease with anti-IA monoclonal antibodies. J Exp Med 158: 1352–1355
Adu D, Williams DG, Quakyi IA, Voller A, Anim-Addo I, Bruce-Tagoe AA, Johnson GD, Holborrow EJ (1982) Anti-ss3DNA and antinuclear antibodies in human malaria. Clin Exp Immunol 49: 310–316
Cattran DC, Ritchie SM, Corey PN (1985) Results of a controlled drug trial in membranous proliferative glomerulonephritis. Kidney Int 27: 436–441
Chapman SJ, Cameron JS, Chantler C (1980) Treatment of mesangiolapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. Arch Dis Child 55: 446–451
Clarkson AR, Woodroffe AJ, Bannister KM, Lomay-Smith JD, Aarons I (1984) The syndrome of IgA nephropathy. Clin Nephrol 21: 7–14
Collaborative study of the adult nephrotic syndrome (1979) A controlled study of short term prednisone treatment in adults with membranous nephropathy. N Engl J Med 301: 1301–1306
Couser WG, Baker PJ, Adler S (1985) Complement mediation of immune glomerular injury. Kidney Int 28: 879–890
Felltren G, Querin S, Chatenoud L, Noel LH, Beuraw G, Tron F, Lesaure P, Bach JF (1985) The effects of cyclosporin in twelve patients with severe systemic lupus. In: Schindler R (ed) Cyclosporin in autoimmune diseases. Springer, Berlin Heidelberg New York, pp 366–372
Flores R, Taube D, Savage COS, Cameron JS, Lockwood CM, Williams DG, Ogg CS (1986) Clinical and immunological evolution of anti-GBM nephritis treated by haemodialysis. Lancet I: 5–8
Hahn E, Ebling F (1984) Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol 132: 187–190
Ikehara S, Shimamura K, Aoyama T, Fuju S, Hamashima Y (1985) Effect of FUT, 175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB × NZW) FI mice. Immunology 55: 595–600
International study of kidney disease in children (1982) Alternate-day steroid therapy in membranous proliferative glomerulonephritis. Kidney Int 21: 150
Johnson TP, Moor J, Austin HA, Balow JE, Anconovych TT, Wilson CB (1985) Therapy of antiglomerular basement membrane disease. Medicine 64: 219–228
Jenette JC, Hyron CP, Iskander SS (1982) Palliative effect of superoxide dismatase in heterologous protein-induced glomerulonephritis. Fed Proc 41: 331
Koyama A, Inage H, Sano M, Narita M, Tojo S, Neild GH, Cameron JS (1985) Platelet involvement in the nephritis of acute serum sickness in rabbits; protection by dipyridamiole and FUT-175. Immunology 61: 368–370
Lewis EJ, Roberts J (1980) Is auto-immunity a common denominator in immune complex disease? Lancet I: 178–180
McGinley E, Watkins R, McLay A, Boulton-Jones JM (1985) Plasma exchange in the treatment of mesangiocapillary glomerulonephritis. Nephron 40: 385–390
Meyrier A, Simon P, Perrett G, Condamin-Meyrier MC (1986) Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. Br Med J 292: 789–792
Neild GH, Ivory, Hiramatsu M, Williams DG (1983) Cyclosporin A inhibits acute serum sickness nephritis in rabbits. Clin Exp Immunol 52: 586–594
Peters DK, Rees AJ, Lockwood CM, Pusey CD (1982) Treatment and prognosis in antibasement membrane antibody mediated nephritis. Trans Proc 14: 513–521
Ponticelli C, Zucchelli P, Imbasciati E (1984) Controlled trial of methyl prednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946–950
Rehan A, Wiggins RC, Johnson KJ (1984) Hydrogen peroxide-induced proteinuria in rats. Kidney Int 25: 217
Robinson DR, Prickett JD, Makelli GT, Steinberg AD, Colvin RB (1986) Dietary fish oil redness progression of established renal disease in (NZB × NZW) FI mice and delays renal disease in BX5B and MRL/1 strains. Arthritis Rheum 29: 539–544
Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet II: 556–560
Terman DS, Buffaloe G, Mattiozi C, Cook G, Tillquist R, Sullivan M, Ayus JC (1979) Extracorporeal immunoadsorption. initial experience in human systemic lupus enythematosus. Lancet II: 824–826
Vilches A, Williams DG (1984) Persistent anti-DNA antibodies and DNA-anti-DNA complexes in post-streptococcal glomerulonephritis. Clin Nephrol 22: 97–101
Williams DG (1984) Treatment of lupus nephritis. Contrib Nephrol 43: 25–35
Wilson CB, Dixon FJ (1986) The renal response to immunological injury, In: Brenner B, Rector FC (eds) The kidney, 3rd edn. W.B. Saunders, Philadelphia, p 800
Van der Woude FJ, Rasmussen N, Lobatto S (1985) Autoantibodies against neutrophils and monocytes. Lancet I: 425–480
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williams, D.G. The treatment of immune glomerular disease. Springer Semin Immunopathol 9, 417–429 (1987). https://doi.org/10.1007/BF00197218
Issue Date:
DOI: https://doi.org/10.1007/BF00197218